Therapeutic drug monitoring of β-lactam antibiotics in the ICU

References

• Sakr Y, Jaschinski U, Wittebole X, et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect Dis. 2018;5:ofy313.
   PubMed Web of Science ®Google Scholar
• Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. JAMA. 2018;319:62–75.
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour C, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–810.
   PubMed Web of Science ®Google Scholar
• Vincent J-L-L, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–2329.
   PubMed Web of Science ®Google Scholar
• Luyt C-E-E, Bréchot N, Trouillet J-L-L, et al. Antibiotic stewardship in the intensive care unit. Crit Care. 2014;18:480.
   PubMed Web of Science ®Google Scholar
• Waele JJ, Dhaese S. Antibiotic stewardship in sepsis management: toward a balanced use of antibiotics for the severely ill patient. Expert Rev Anti Infect Ther. 2019;17:89–97.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Bassetti M, Francois B, et al. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Med. 2017;43:1187–1197.
   PubMed Web of Science ®Google Scholar
• Cotta M, Roberts JA, Tabah A, et al. Antimicrobial stewardship of β-lactams in intensive care units. Expert Rev Anti Infect Ther. 2014;12:581–595.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Roger C, Waele JJ. Personalized antibiotic dosing for the critically ill. Intensive care medicine. 2019;45(5):715-718..
   Google Scholar
• Jelliffe RW, Schumitzky A, Guilder M, et al. Individualizing drug dosage regimens. Ther Drug Monit. 1993;15:380–393.
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev. 2013;65:1053–1090.
   PubMed Web of Science ®Google Scholar
• Veiga RP, Paiva J-A-A. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients. Crit Care. 2018;22:233.
   PubMed Web of Science ®Google Scholar
• Dhaese SA, Farkas A, Colin P, et al. Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. J Antimicrob Chemother. 2019;74:432–441.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072–1083.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-system pharmacists, and the society of infectious diseases pharmacists. Clin Infect Dis Official Publ Infect Dis Soc Am. 2009;49:325–327.
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Ch. 2008;53:24–34.
   PubMed Web of Science ®Google Scholar
• Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011;15:R206.
   PubMed Web of Science ®Google Scholar
• Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient — concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.
   PubMed Web of Science ®Google Scholar
• Varghese JM, Roberts JA, Lipman J. antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin. 2011;27:19–34.
   PubMed Web of Science ®Google Scholar
• Huttner A, Dach EV, Renzoni A, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents. 2015;45:385–392.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Lipman J, Mouton JW, et al. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med. 2015;36:136–153.
   PubMed Web of Science ®Google Scholar
• Carrié C, Petit L, d’Houdain N, et al. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study. Int J Antimicrob Agents. 2018;51:443–449.
   PubMed Web of Science ®Google Scholar
• Sumi CD, Heffernan AJ, Lipman J, et al. What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review. Clin Pharmacokinet. 2019;58:1407–1443.
   PubMed Web of Science ®Google Scholar
• Imani S, Buscher H, Marriott D, et al. Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72:2891–2897.
   PubMed Web of Science ®Google Scholar
• Quinton MC, Bodeau S, Kontar L, et al. Neurotoxic concentration of piperacillin during continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2017;61(9):e00654-17.
   Web of Science ®Google Scholar
• Beumier M, Casu G, Hites M, et al. Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015;81:497–506.
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, Lipman J, et al. The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: an appraisal utilizing antibiotics. Adv Drug Deliv Rev. 2018;123:65–74.
   PubMed Web of Science ®Google Scholar
• Ramon-Lopez A, Allen JM, Thomson AH, et al. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. J Antimicrob Chemother. 2015;70:882–890.
   PubMed Web of Science ®Google Scholar
• Weber N, Jackson K, McWhinney B, et al. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. J Infect Chemother. 2019;25:503–508.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Udy AA, Jarrett P, et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. J Antimicrob Chemother. 2015;70:1495–1502.
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Thengyai S, Wongpoowarak W, et al. Population Pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59:2995–3001.
   PubMed Web of Science ®Google Scholar
• Alobaid AS, Wallis SC, Jarrett P, et al. Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients. In: Antimicrobial agents and chemotherapy. 2017;61(3): e01276-16.
   Google Scholar
• Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of meropenem in critically ill patients. Antimicrob Agents Chemother. 2016;60:4577–4584.
   PubMed Web of Science ®Google Scholar
• Sime F, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol. 2015;24:1–6.
   PubMed Web of Science ®Google Scholar
• Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142:30–39.
   PubMed Web of Science ®Google Scholar
• Eyler RF, Shvets K. Clinical Pharmacology of Antibiotics. Clin J Am Soc Nephrol. 2019;14:1080–1090.
   PubMed Web of Science ®Google Scholar
• Lobo SM. Sequential C-reactive protein measurements in patients with serious infections: does it help? Crit Care Lond Engl. 2012;16:130.
   PubMed Web of Science ®Google Scholar
• Jang Y-R, Eom JS, Chung W, et al. Prolonged fever is not a reason to change antibiotics among patients with uncomplicated community-acquired acute pyelonephritis. Medicine (Baltimore). 2019;98:e17720.
   PubMed Web of Science ®Google Scholar
• Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64:iii1–iii55.
   PubMed Web of Science ®Google Scholar
• Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. Critical care. 2017;21(1):276.
   Google Scholar
• Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. Jama. 2020;323:527–537.
   PubMed Web of Science ®Google Scholar
• Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46:12–20.
   PubMed Web of Science ®Google Scholar
• Hammond DA, Smith MN, Li C, et al. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis. 2017;64:666–674.
   PubMed Web of Science ®Google Scholar
• Pill MW, O’Neill CV, Chapman MM, et al. Suspected acute interstitial nephritis induced by piperacillin‐tazobactam. Pharmacother J Hum Pharmacol Drug Ther. 1997;17:166–169.
   Google Scholar
• Michel DM, Kelly CJ. Acute interstitial nephritis. J Am Soc Nephrol Jasn. 1998;9:506–515.
   PubMed Web of Science ®Google Scholar
• Rodriguez CA, Agudelo M, Zuluaga AF, et al. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products. Int J Antimicrob Agents. 2017;49:189–197.
   PubMed Web of Science ®Google Scholar
• Katsube T, Yano Y, Yamano Y, et al. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. J Pharm Sci. 2008;97:4108–4117.
   PubMed Web of Science ®Google Scholar
• Bowker KE, Noel AR, Tomaselli SG, et al. Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in pseudomonas aeruginosa and acinetobacter baumannii in an In Vitro pharmacokinetic model. Antimicrob Agents Chemother. 2012;56:5009–5015.
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg IA, Kate MT,T, Goessens WH, et al. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental klebsiella pneumoniae lung infection. Antimicrob Agents Chemother. 2006;50:2919–2925.
   PubMed Web of Science ®Google Scholar
• Lamp KC, Vickers MK. Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against escherichia coli strains with various levels of resistance. Antimicrob Agents Chemother. 1998;42:231–235.
   PubMed Web of Science ®Google Scholar
• MacGowan AP, Noel AR, Rogers CA, et al. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 2004;48:2599–2603.
   PubMed Web of Science ®Google Scholar
• Gustafsson I, Löwdin E, Odenholt I, et al. Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrob Agents Chemother. 2001;45:2436–2440.
   PubMed Web of Science ®Google Scholar
• Woodnutt G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999;43:29–34.
   PubMed Web of Science ®Google Scholar
• Sevillano D, Calvo A, M-JJ G, et al. Bactericidal activity of amoxicillin against non-susceptible streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. J Antimicrob Chemother. 2004;54:1148–1151.
   PubMed Web of Science ®Google Scholar
• Vourli S, Tsala M, Kotsakis S, et al. Comparison of short versus prolonged infusion of standard dose of meropenem against carbapenemase-producing klebsiella pneumoniae isolates in different patient groups: a pharmacokinetic–pharmacodynamic approach. J Pharm Sci. 2016;105:1513–1518.
   PubMed Web of Science ®Google Scholar
• Tsala M, Vourli S, Kotsakis S, et al. Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications. J Med Microbiol. 2016;65:211–218.
   PubMed Web of Science ®Google Scholar
• Manduru M, Mihm LB, White RL, et al. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 1997;41:2053–2056.
   PubMed Web of Science ®Google Scholar
• Soontornpas C, Saraya S, Chulasiri M, et al. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis. Int J Antimicrob Agents. 2005;26:403–407.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Larosa M, Marchetti F. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion. J Antimicrob Chemother. 2003;52:1047–1048.
   PubMed Web of Science ®Google Scholar
• White RL, Friedrich LV, Manduru M, et al. Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis. Diagn Microbiol Infect Dis. 2001;39:39–47.
   PubMed Web of Science ®Google Scholar
• Mouton J, Hollander JD. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38:931–936.
   PubMed Web of Science ®Google Scholar
• Cappelletty D, Kang S, Palmer S, et al. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1995;39:1797–1801.
   PubMed Web of Science ®Google Scholar
• Heffernan A, Sime F, Lipman J, et al. Individualising therapy to minimize bacterial multidrug resistance. Drugs. 2018;78:621–641.
   PubMed Web of Science ®Google Scholar
• Tam VH, Chang K-T-T, Zhou J, et al. Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017;72:1421–1428.
   PubMed Web of Science ®Google Scholar
• Felton T, Goodwin J, O’Connor L, et al. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57:5811–5819.
   PubMed Web of Science ®Google Scholar
• Ariano RE, Nyhlén A, Donnelly PJ, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2004;39:32–38.
   PubMed Web of Science ®Google Scholar
• Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51:1725–1730.
   PubMed Web of Science ®Google Scholar
• McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–351.
   PubMed Web of Science ®Google Scholar
• Wong G, Taccone F, Villois P, et al. β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. J Antimicrob Chemother. 2020;75:429–433.
   PubMed Web of Science ®Google Scholar
• Aitken SL, Altshuler J, Guervil DJ, et al. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015;45:541–544.
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013;68:900–906.
   PubMed Web of Science ®Google Scholar
• Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Ch. 2010;54:4360–4367.
   PubMed Web of Science ®Google Scholar
• Boschung-Pasquier L, Atkinson A, Kastner LK, et al. Cefepime neurotoxicity: thresholds and risk factors. A Retrospective Cohort study. Clin Microbiol Infect Official Publ European Soc Clin Microbiol Infect Dis. 2019;26:333–339.
   PubMed Web of Science ®Google Scholar
• Mouton J, Brown D, Apfalter P, et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect. 2012;18:E37–E45.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Muller AE, Canton R, et al. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2018;73:564–568.
   PubMed Web of Science ®Google Scholar
• Mabilat C, Gros MF, Nicolau D, et al. Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. Eur J Clin Microbiol. 2019;39(5):791-797.
   Google Scholar
• Winter BCMD, Neumann I, Hest RMV, et al. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit. 2009;31:382–390.
   PubMed Web of Science ®Google Scholar
• Mould DR, Upton RN, Wojciechowski J. Dashboard systems: implementing pharmacometrics from bench to bedside. Aaps J. 2014;16:925–937.
   PubMed Web of Science ®Google Scholar
• Felton TW, Roberts JA, Lodise TP, et al. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother. 2014;58:4094–4102.
   PubMed Web of Science ®Google Scholar
• Meer AFVD, Marcus MAE, Touw DJ, et al. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit. 2011;33:133–146.
   PubMed Web of Science ®Google Scholar
• Carlier M, Stove V, Waele JJD, et al. Ultrafast quantification of β-lactam antibiotics in human plasma using UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;978–979:89–94.
   PubMed Web of Science ®Google Scholar
• Mortensen JS, Jensen BP, Zhang M, et al. Preanalytical stability of piperacillin, tazobactam, meropenem, and ceftazidime in plasma and whole blood using liquid chromatography–tandem mass spectrometry. Ther Drug Monit. 2019;41:538–543.
   PubMed Web of Science ®Google Scholar
• Carlier M, Verstraete AG, Waele JJD, et al. Stability of amoxicillin and amoxicillin/clavulanic acid reconstituted in isotonic saline. J Chemother Florence Italy. 2016;29:54–56.
   PubMed Web of Science ®Google Scholar
• Arlicot N, Marie A, Cade C, et al. Stability of amoxicillin in portable pumps is drug concentration dependent. Pharmazie. 2011;66:631–632.
   PubMed Web of Science ®Google Scholar
• Airaudo CB, Gayte-Sorbier A, Bianchi C, et al. Interactions between six psychotherapeutic drugs and plastic containers. Influence of plastic material and infusion solutions. Int J Clin Pharmacol Ther Toxicol. 1993;31:261–266.
   PubMed Web of Science ®Google Scholar
• Carlier M, Stove V, Wallis SC, et al. Assays for therapeutic drug monitoring of β-lactam antibiotics: A structured review. Int J Antimicrob Agents. 2015;46:367–375.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on bioanalytical method validation [Internet]. 2011 [cited 2020 Mar 18]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf.
   Google Scholar
• Carlier M, Athanasopoulos A, Borrey D, et al. Proficiency testing for meropenem and piperacillin therapeutic drug monitoring: preliminary results from the belgian society on infectiology and clinical microbiology pharmacokinetic-pharmacodynamic working group. Ther Drug Monit. 2018;40:156–158.
   PubMed Web of Science ®Google Scholar
• Sandegren L. Selection of antibiotic resistance at very low antibiotic concentrations. Ups J Med Sci. 2014;119:103–107.
   PubMed Web of Science ®Google Scholar
• Schoenenberger-Arnaiz J, Ahmad-Diaz F, Miralbes-Torner M, et al. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients. Eur J Hosp Pharm. 2020;27(e1):e30-e35.
   PubMedGoogle Scholar
• Wong G, Briscoe S, McWhinney B, et al. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother. 2018;73:3087–3094.
   PubMed Web of Science ®Google Scholar
• Colin P, Ferdinande K, Care DJ. Target controlled infusion in the ICU: an opportunity to optimize antibiotic therapy. In: Vincent JL, editor. Annual update in intensive care and emergency medicine 2019. annual update in intensive care and emergency medicine. Cham: Springer. 2019:497-506.
   Google Scholar
• Kim A, Banevicius M, Nicolau DP. In Vivo pharmacodynamic profiling of doripenem against pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother. 2008;52:2497–2502.
   PubMed Web of Science ®Google Scholar
• Fantin B, Leggett J, Ebert S, et al. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother. 1991;35:1413–1422.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Kanazawa K, Takemoto K, et al. Therapeutic effect of meropenem on an experimental guinea pig model of meningitis with type b β-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae. J Infect Chemother. 2013;19:593–598.
   PubMed Web of Science ®Google Scholar
• Leggett J, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989;159:281–292.
   PubMed Web of Science ®Google Scholar
• Timsit J-F-F, Bassetti M, Cremer O, et al. Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Med. 2019;45:172–189.
   PubMed Web of Science ®Google Scholar
• Sime F, Roberts MS, Tiong I, et al. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. J Antimicrob Chemother. 2015;70:2369–2375.
   PubMed Web of Science ®Google Scholar
• Carrié C, Chadefaux G, Sauvage N, et al. Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study. Crit Care Lond Engl. 2019;23:379.
   PubMed Web of Science ®Google Scholar
• Lancet T. Artificial intelligence in health care: within touching distance. Lancet. 2018;390:2739.
   PubMed Web of Science ®Google Scholar
• Meyer A, Zverinski D, Pfahringer B, et al. Machine learning for real-time prediction of complications in critical care: a retrospective study. Lancet Respir Med. 2018;6:905–914.
   PubMed Web of Science ®Google Scholar
• Roimi M, Neuberger A, Shrot A, et al. Early diagnosis of bloodstream infections in the intensive care unit using machine-learning algorithms. Intens Care Med. 2020;46(3):454-462.
   PubMed Web of Science ®Google Scholar
• Peiffer-Smadja N, Rawson TM, Ahmad R, et al. Machine learning for clinical decision support in infectious diseases: a narrative review of current applications. Clin Microbiol Infect. 2020;26(5):584–595.
   PubMed Web of Science ®Google Scholar
• Tang J, Liu R, Zhang Y-L-L, et al. Application of machine-learning models to predict tacrolimus stable dose in renal transplant recipients. Sci Rep. 2017;7:42192.
   PubMed Web of Science ®Google Scholar
• Liu R, Li X, Zhang W, et al. Comparison of nine statistical model based warfarin pharmacogenetic dosing algorithms using the racially diverse international warfarin pharmacogenetic consortium cohort database. PloS One. 2015;10:e0135784.
   PubMed Web of Science ®Google Scholar
• Poynton M, Choi B, Kim Y, et al. Machine learning methods applied to pharmacokinetic modelling of remifentanil in healthy volunteers: a multi-method comparison. J Int Med Res. 2009;37:1680–1691.
   PubMed Web of Science ®Google Scholar
• Brier M, Zurada J, Aronoff G. Neural network predicted peak and trough gentamicin concentrations. Pharm Res. 1995;12:406–412.
   PubMed Web of Science ®Google Scholar
• Valero YCG, Wallis SC, Lipman J, et al. Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. Bioanalysis. 2018;10:407–423.
   PubMed Web of Science ®Google Scholar
• Herregodts J, Vooren VS, Deschuyteneer E, et al. Measuring antibiotics in exhaled air in critically ill, non-ventilated patients: A feasibility and proof of concept study. J Crit Care. 2019;51:46–50.
   PubMed Web of Science ®Google Scholar